![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M Lee, KH Yang and NE Kaminski
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, USA.
Anandamide (arachidonylethanolamide), isolated from the porcine brain, and 2-arachidonyl-glycerol (2-Ara-Gl), derived from the canine gut, are two recently identified putative endogenous cannabinoid receptor ligands. Both ligands have been reported to possess binding affinity for cannabinoid receptor subtypes, CB1 and CB2. The objective of the present studies was to investigate the immunomodulatory effects of both of these ligands in B6C3F1 mouse splenocytes. 2-Ara-Gl produced a marked and dose-related inhibition of the mixed lymphocyte response, anti-CD3 mAb-induced T-cell proliferation and LPS-induced B-cell proliferation, whereas having no inhibitory effect on phorbol-12- myristate-13-acetate/ionomycin-induced cell proliferation. Interestingly, the inhibitory effects by 2-Ara-Gl on proliferation were at least dependent in part on cell density. At high cell density, 2-Ara- Gl enhanced lymphoproliferation whereas exhibiting marked inhibitory activity at low cell density. Similarly, in vitro primary immunoglobulin M antibody-forming cell responses which are dependent on high cell density also were found to be enhanced by 2-Ara-Gl. Conversely, anandamide exhibited no inhibitory effects on cell proliferative responses to stimulation by anti-CD3 mAb, lipopolysaccharide or phorbol-12-myristate-13-acetate/ionomycin treatment. Anandamide also showed no effect on the in vitro sheep erythrocyte antibody-forming cell response. Although shown previously to markedly inhibit forskolin-stimulated cyclic AMP accumulation, 2-Ara- Gl exhibited no effect on basal adenylate cyclase activity in splenocytes. Additionally, anandamide showed negligible inhibitory effects at extremely high concentrations on forskolin-stimulated adenylate cyclase activity and no effect on basal adenylate cyclase activity in splenocytes.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  D. Schneider, M. A. Manzan, R. B. Crawford, W. Chen, and N. E. Kaminski 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Mediated Impairment of B Cell Differentiation Involves Dysregulation of Paired Box 5 (Pax5) Isoform, Pax5a J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 463 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oka, J. Wakui, S. Ikeda, S. Yanagimoto, S. Kishimoto, M. Gokoh, M. Nasui, and T. Sugiura Involvement of the Cannabinoid CB2 Receptor and Its Endogenous Ligand 2-Arachidonoylglycerol in Oxazolone-Induced Contact Dermatitis in Mice J. Immunol., December 15, 2006; 177(12): 8796 - 8805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Rockwell, N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel, and N. E. Kaminski Interleukin-2 Suppression by 2-Arachidonyl Glycerol Is Mediated through Peroxisome Proliferator-Activated Receptor {gamma} Independently of Cannabinoid Receptors 1 and 2 Mol. Pharmacol., July 1, 2006; 70(1): 101 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. F. Kaplan, Y. Ouyang, C. E. Rockwell, G. K. Rao, and N. E. Kaminski 2-Arachidonoyl-glycerol suppresses interferon-{gamma} production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2 J. Leukoc. Biol., June 1, 2005; 77(6): 966 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oka, S. Yanagimoto, S. Ikeda, M. Gokoh, S. Kishimoto, K. Waku, Y. Ishima, and T. Sugiura Evidence for the Involvement of the Cannabinoid CB2 Receptor and Its Endogenous Ligand 2-Arachidonoylglycerol in 12-O-Tetradecanoylphorbol-13-acetate-induced Acute Inflammation in Mouse Ear J. Biol. Chem., May 6, 2005; 280(18): 18488 - 18497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kishimoto, M. Muramatsu, M. Gokoh, S. Oka, K. Waku, and T. Sugiura Endogenous Cannabinoid Receptor Ligand Induces the Migration of Human Natural Killer Cells J. Biochem., February 1, 2005; 137(2): 217 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oka, S. Ikeda, S. Kishimoto, M. Gokoh, S. Yanagimoto, K. Waku, and T. Sugiura 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils J. Leukoc. Biol., November 1, 2004; 76(5): 1002 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kishimoto, Y. Kobayashi, S. Oka, M. Gokoh, K. Waku, and T. Sugiura 2-Arachidonoylglycerol, an Endogenous Cannabinoid Receptor Ligand, Induces Accelerated Production of Chemokines in HL-60 Cells J. Biochem., April 1, 2004; 135(4): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kishimoto, M. Gokoh, S. Oka, M. Muramatsu, T. Kajiwara, K. Waku, and T. Sugiura 2-Arachidonoylglycerol Induces the Migration of HL-60 Cells Differentiated into Macrophage-like Cells and Human Peripheral Blood Monocytes through the Cannabinoid CB2 Receptor-dependent Mechanism J. Biol. Chem., June 27, 2003; 278(27): 24469 - 24475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. BERDYSHEV, P. C. SCHMID, R. J. KREBSBACH, and H. H. O. SCHMID Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells FASEB J, October 1, 2001; 15(12): 2171 - 2178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Iwamura, H. Suzuki, Y. Ueda, T. Kaya, and T. Inaba In Vitro and in Vivo Pharmacological Characterization of JTE-907, a Novel Selective Ligand for Cannabinoid CB2 Receptor J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 420 - 425. [Abstract] [Full Text]
|
|
|
|
|
|
W. Gonsiorek, C. Lunn, X. Fan, S. Narula, D. Lundell, and R. W. Hipkin Endocannabinoid 2-Arachidonyl Glycerol Is a Full Agonist through Human Type 2 Cannabinoid Receptor: Antagonism by Anandamide Mol. Pharmacol., May 1, 2000; 57(5): 1045 - 1050. [Abstract] [Full Text]
|
|
|
|
|
|
T. Sugiura, S. Kondo, S. Kishimoto, T. Miyashita, S. Nakane, T. Kodaka, Y. Suhara, H. Takayama, and K. Waku Evidence That 2-Arachidonoylglycerol but Not N-Palmitoylethanolamine or Anandamide Is the Physiological Ligand for the Cannabinoid CB2 Receptor. COMPARISON OF THE AGONISTIC ACTIVITIES OF VARIOUS CANNABINOID RECEPTOR LIGANDS IN HL-60 CELLS J. Biol. Chem., January 7, 2000; 275(1): 605 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Portier, M. Rinaldi-Carmona, F. Pecceu, T. Combes, C. Poinot-Chazel, B. Calandra, F. Barth, G. L. Fur, and P. Casellas SR 144528, an Antagonist for the Peripheral Cannabinoid Receptor that Behaves as an Inverse Agonist J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 582 - 589. [Abstract] [Full Text]
|
|
|
|
|
|
T. Sugiura, T. Kodaka, S. Nakane, T. Miyashita, S. Kondo, Y. Suhara, H. Takayama, K. Waku, C. Seki, N. Baba, et al. Evidence That the Cannabinoid CB1 Receptor Is a 2-Arachidonoylglycerol Receptor. STRUCTURE-ACTIVITY RELATIONSHIP OF 2-ARACHIDONOYLGLYCEROL, ETHER-LINKED ANALOGUES, AND RELATED COMPOUNDS J. Biol. Chem., January 29, 1999; 274(5): 2794 - 2801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Varga, J. A. Wagner, D. T. Bridgen, and G. Kunos Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension FASEB J, August 1, 1998; 12(11): 1035 - 1044. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. De Petrocellis, D. Melck, A. Palmisano, T. Bisogno, C. Laezza, M. Bifulco, and V. Di Marzo The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation PNAS, July 7, 1998; 95(14): 8375 - 8380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ouyang, S. G. Hwang, S. H. Han, and N. E. Kaminski Suppression of Interleukin-2 by the Putative Endogenous Cannabinoid 2-Arachidonyl-Glycerol Is Mediated through Down-regulation of the Nuclear Factor of Activated T Cells Mol. Pharmacol., April 1, 1998; 53(4): 676 - 683. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Valk, S. Verbakel, Y. Vankan, S. Hol, S. Mancham, R. Ploemacher, A. Mayen, B. Lowenberg, and R. Delwel Anandamide, a Natural Ligand for the Peripheral Cannabinoid Receptor Is a Novel Synergistic Growth Factor for Hematopoietic Cells Blood, August 15, 1997; 90(4): 1448 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bisogno, S. Maurelli, D. Melck, L. De Petrocellis, and V. Di Marzo Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes J. Biol. Chem., February 7, 1997; 272(6): 3315 - 3323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bayewitch, M.-H. Rhee, T. Avidor-Reiss, A. Breuer, R. Mechoulam, and Z. Vogel (-)-Delta^9-Tetrahydrocannabinol Antagonizes the Peripheral Cannabinoid Receptor-mediated Inhibition of Adenylyl Cyclase J. Biol. Chem., April 26, 1996; 271(17): 9902 - 9905. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
